Meeting
2014 ASCO Annual Meeting
Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results.
Authors
Paolo Ghia
Università Vita e Salute; San Raffaele Scientific Institute, Milano, Italy
Paolo Ghia , Susan Mary O'Brien , Peter Hillmen , Richard R. Furman , Steven E. Coutre , Jeff Porter Sharman , Bruce D. Cheson , John M. Pagel , Jacqueline Claudia Barrientos , Andrew David Zelenetz , Thomas J. Kipps , Ian Flinn , Herbert Aaron Eradat , Nicole Lamanna , Michael J. Hallek , Bertrand Coiffier , Andrew Pettitt , Wei Ye , Thomas Michael Jahn , Lynne I. Wagner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT01539512
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 7099)
DOI
10.1200/jco.2014.32.15_suppl.7099
Abstract #
7099
Poster Bd #
384
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
An evaluation of the chronic lymphocytic leukemia (CLL) international prognostic index as a prognostic tool in patients with relapsed/refractory CLL in idelalisib phase 3 randomized studies.
First Author: Jacob Drobnyk Soumerai
Poster
2016 ASCO Annual Meeting
Updated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).
First Author: Jeffrey Alan Jones
Poster
2016 ASCO Annual Meeting
Outcomes of patients with relapsed and refractory chronic lymphocytic leukemia (CLL) who discontinue idelalisib treatment.
First Author: Jennifer R. Brown
Poster
2014 ASCO Annual Meeting
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia.
First Author: Gilles A. Salles